![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, March 04, 2010 7:39:32 PM
NEW BRUNSWICK, N.J., March 4 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) reported today the redemption of all of the outstanding convertible debentures and Series A warrants held by YA Global Investments, LP (YA Global). The redemption amount, including accrued interest, paid by Senesco to YA Global was $2,194,845.
"This transaction significantly improves our capital structure by eliminating the potential for approximately 16,000,000 shares of future dilution and, as with the recently completed Stanford agreement, should enable us to more easily identify suitable financing," said Harlan Waksal, M.D., Senesco's Chairman of the Board. "We are confident that we have taken the appropriate steps to enhance our attractiveness as an investment opportunity, and look forward to the continued development of SNS-01, our multiple myeloma drug candidate."
Senesco utilized funds secured in the recent $3 million credit facility from JMP Securities in order to complete this transaction.
About Senesco Technologies, Inc.
Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate additional financings; the ability of the Company to file an IND for SNS-01, its multiple myeloma drug candidate; the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the successful conversion of the Company's letter of intent into a license agreement; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Company Contact:
Investor Relations Contact:
Senesco Technologies, Inc.
FD
Jack Van Hulst
Brian Ritchie
Chief Executive Officer
(brian.ritchie@fd.com)
(jvanhulst@senesco.com)
(212) 850-5600
(732) 296-8400
Visit my biotech investing board!: BioShockers
Do your own DD before investing.
GLTA.
Recent ELOX News
- Eloxx Pharmaceuticals Provides Pipeline and Financing Updates • GlobeNewswire Inc. • 07/11/2024 03:46:35 PM
- Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates • GlobeNewswire Inc. • 04/16/2024 11:30:00 AM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:02:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/29/2024 08:11:23 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 03/21/2024 06:20:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/14/2024 08:30:38 PM
- Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases • GlobeNewswire Inc. • 03/13/2024 03:42:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:33:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:33:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:32:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:32:14 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/25/2024 02:44:31 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/24/2024 10:11:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 10:10:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:11:02 PM
- Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update • GlobeNewswire Inc. • 11/13/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:26:20 PM
- Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria • GlobeNewswire Inc. • 10/09/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 08:05:43 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/20/2023 05:26:02 PM
- Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 09/19/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 12:05:57 PM
- Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome • GlobeNewswire Inc. • 09/18/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/15/2023 09:15:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 02:14:41 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM